Please assess the completion status of the following clinical trial:

Trial Title: Autologous EBV-specific Cytotoxic T Cells for the Treatment of Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 4 systemic lupus criteria of the American College of Rheumatology with antinuclear antibodies\> 1:80~* Age greater than or equal to 18 years~* Lupus serologically active without active serious disease (Kidney, CNS)~* Anti-native DNA Ac positive and / or C3 or C4 low~* SLEDAI greater than or equal to 2 at baseline~* Serology HBV, HCV, HIV, HTLV-1, syphilis: Negative J-30 before sample~* Hemoglobin \>11g/dL~* Prednisone dose \<15 mg / day with a stable dose within 30 days previous injection~* Immunosuppressive treatments which dosage has not been increased for at least 3 months before enrollment~* Agreement telephone and / or mail for coordinating investigator inclusion~* Social ensured Patient~* EBV positive serology~Exclusion Criteria:~* Evolving severe lupus, requiring high dose corticosteroids and / or immunosuppressive therapy~* Psychiatric disorders~* Predicted Failure to monitoring compliance with impossibility~* Infectious Episode underway~* Evolutionary Cancer~* Risk of death within 6 months~* Consent Refusal~* Pregnancy~* Nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Autologous EBV specific CTL infusion (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).